A Comparative Study on Efficacy and Safety of Propofol versus Dexmedetomidine in Sleep Apnea Patients undergoing Drug-Induced Sleep Endoscopy: A CONSORT-Prospective, Randomized, Controlled Clinical Trial

L. L. Zhao,1,2 H. Liu,2 Y. Y. Zhang,2 J. Q. Wei,2 Y. Han,2 L. Han,2 and J. P. Yang1

1Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou 215006, Jiangsu, China
2Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221004, Jiangsu, China

Correspondence should be addressed to J. P. Yang; 20144132046@stu.suda.edu.cn

Received 20 July 2018; Revised 22 August 2018; Accepted 14 October 2018; Published 1 November 2018

Academic Editor: Michael Frass

Copyright © 2018 L. L. Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Patients with SAHS have episodes of apnea or hypopnea due to the obstructive upper airways. Surgical operations are often considered as the alternative treatments in patients with SAHS. Therefore, to achieve site-specific surgical modification of the upper airway, it is vital to evaluate upper airway obstruction [1]. DISE can be used to observe the obstructive position and the anatomical factors causing local obstruction in the patients with SAHS under the condition of “sleep” and provide an important evidence for the reconstruction of the upper airway in these patients. A great number of studies have reported the validity and reliability of DISE. At present, the major drugs in clinical use for DISE are mainly confined to intravenous anesthetics and sedative hypnotic drugs, such as propofol, etomidate, and benzodiazepines [2]. Although studies showed that the target-controlled infusion of propofol can accurately control the depth of sedation during DISE, the ventilatory response to hypoxic can be depressed by larger doses of propofol during conscious sedation [3]. Furthermore, the sleep induced by all of these drugs used in the clinic for DISE is not in accordance with the natural physiological sleep, which interferes with the dynamic anatomical changes of airway causing apnea in the patients with SAHS.

Dexmedetomidine, a highly selective alpha 2 adrenergic receptor agonist, has a characteristic sedation similar to natural physiological sleep in conscious patients without significant respiratory depression [4, 5]. Therefore, dexmedetomidine is alternative drug used for conscious sedation in
patients with SAHS undergoing DISE. However, the safety and efficacy of dexmedetomidine as a sedative used for DISE in the patients with SAHS are unknown.

Thus, in the present study, we compared efficacy and safety of dexmedetomidine with propofol for DISE in patients with SAHS and provided clinical evidences for dexmedetomidine as a novel sleep induced drug applied for endoscopy in patients with SAHS.

2. Material and Methods

2.1. Study Protocol. This prospective, randomized, controlled clinical trial was conducted at the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China, and the protocol of this study was approved by the Institutional Medical Ethics Committee of Xuzhou Medical University, in accordance with the approved guidelines. Written informed consent for participation in this study was obtained from all the participants before the start of the study. This trial is registered at the Chinese Clinical Trial Registry (ChiCTR-IOR-17010423). The sample size of the study was calculated according to the previous studies [6–9] and was based on a pilot study.

2.2. Patients. A group of 88 consecutive patients including 82 male and 6 female patients diagnosed with SAHS by the Department of Otorhinolaryngology, Head and Neck Surgery in the Affiliated Hospital of Xuzhou Medical University, aged between 33 and 60 years, were enrolled. Exclusion criteria included electrocardiogram suggesting bradycardia or cardiac conduction block, previous general anesthesia or recent administration of sedatives or analgesics, any known allergy to the study drugs, mental disease, nervous system disease, or developmental delay.

2.3. Randomization and Blinding. All patients were assigned by dint of a computer-generated random number table into one of two groups (n = 44): group D and group P. Drug-induced sleep was carried out by one experienced anesthetist, and the otolaryngologist was blinded to which kind of drug performed endoscopy.

2.4. Drug-Induced Sleep Endoscopy. All patients entered the examination room with quiet and dim light. The age, body mass index (BMI), apnea hypopnea index (AHI), and lowest oxygen saturation (LSaO2) of all patients in the two groups during polysomnography were recorded before drug-induced sleep endoscopy. All patients were not given any preoperative medication, with fasting for 6 hours before the examination, and lied on the examination couch for 10 minutes. Standard monitoring (MAP, SPO2, and ECG) was applied, and a peripheral intravenous cannula insertion was performed. 3-5 drops of ephedrine were given in the nasal cavity of patients for endoscopy. If the systolic pressure was higher than 180 mmHg or the diastolic pressure was above 110 mmHg, urapidil hydrochloride 5-10 mg was administered. The anaesthetist monitored patients’ vital signs and administered drugs. Endoscopy was performed by the same otolaryngologist in this trial.

Patients in group D received continuous intravenous infusion of dexmedetomidine 1 μg/kg (200 mg diluted in 50 ml saline) over 15 minutes before the endoscopy, and the maximum dosage of dexmedetomidine can be increased to 2 μg/kg according to progress of endoscopic operation and the movement of the patients. Propofol 2 mg/kg was intravenously administrated in group P; then 1 mg/kg was given for maintenance, and the maximum dosage of propofol was 3 mg/kg. Endoscopy was performed by one otolaryngologist when patients disappeared the eyelash reflex. Before falling asleep, the electronic nasopharyngolaryngoscope was gently inserted and kept in the nasal cavity through checking the nasal cavity by the otolaryngologist, carefully holding the endoscopy until patient fell asleep. When the patient appeared to have respiratory effort or apnea, the degree of pharyngeal collapse of patients from the nasopharynx to larynx was recorded and saved as video for the later analysis.

The MAP of patients decreased ≥ 30% of the basic value, ephedrine 5-10 mg was intravenously injected, atropine 0.25-0.5 mg was infused when the HR was less than 50 bpm, and SpO2 of patients was lower than 50%; jaw was lifted to relieve obstruction and mask assisted ventilation with oxygen during endoscopy.

2.5. Outcome Measures. All related data were collected by another anaesthetist not directly involved in anaesthesia for the patient. The HR, SBP, DBP, and SpO2 of patients at time points of preadministration of drugs (T0), immediately falling asleep patients (T1), during endoscopic operation (T2), and completion of the endoscopy (T3) were recorded respectively. The time to fall asleep (T1-T0) was calculated. Duration of endoscopic examination, the wakeup time, number of mask assisted ventilations for patients, satisfaction of patients and endoscopic performers, and false positive cases of SAHS of patients in the two groups were recorded.

2.6. Postoperative Care. After completion of endoscopy, the drugs were taken off. After they were fully awake, patients continued to be carefully observed for 30 min and vital signs and SpO2 of patients were monitored, and the patients were allowed to be out of the examination room without any symptoms of dizziness, nausea, and vomiting.

2.7. Statistical Analysis. Data analyses first entailed characterization of participants using descriptive and summary statistics (mean ± SD for age, BMI, AHI, LSaO2, HR, MAP, SpO2, time to fall asleep, duration of endoscopic examination, and the wakeup time; percentages for sex ratio, mask assisted ventilation, the satisfaction of patients and endoscopic performers, and false positive cases of SAHS of patients). Data between two groups were compared using Student’s t-test, or Pearson’s chi-squared test. Statistical analyses of data were generated using Statistical Package for Social Science, version 11.0 (SPSS II.0). All p values given are based on two-tailed tests and a p value of < 0.05 was considered statistically significant.
Enrollment

Assessed for eligibility (n=88)

Randomised (n=88)

Allocation

Allocated to the group D (n=44)
Received allocated intervention (n=44)

Allocated to the group P (n=44)
Received allocated intervention (n=44)

Flow up

Lost to follow up (n=0)

Lost to follow up (n=0)

Analysis

Analysed (n=44)

Analysed (n=44)

Figure 1: CONSORT flow diagram of patients included in the study.

Table 1: Demographics of analyzed patients.

|                | group D       | group P       |
|----------------|---------------|---------------|
| Age; years     | 42.5 ± 6.0    | 43.2 ± 6.6    |
| BMI; kg/m²     | 28.0 ± 3.5    | 28.9 ± 3.1    |
| Gender; male:female | 42:2 | 40:4          |
| AHI; events/hour | 56.3 ± 21.5  | 54.3 ± 20.4  |
| LSaO₂; %       | 65.7 ± 0.21   | 65.8 ± 0.12   |

Data are presented as mean ± SD, or number of patients.

3. Results

Figure 1 shows the CONSORT flow diagram for patients in the present study. A total of 88 patients enrolled successfully completed DISE with propofol and dexmedetomidine in this study, and the data for all of these patients were analyzed.

Patient demographic data are shown in Table 1. There was no significant difference between the two groups in demographic data (age: 42.5 ± 6.0 in group D vs 43.2 ± 6.6 in group P; sex: 42/2 (male/female) in group D vs 40/4 (male/female) in group P), BMI (28.0 ± 3.5 in group D vs 28.9 ± 3.1 in group P), AHI (56.3 ± 21.5 in group D vs 54.3 ± 20.4 in group P), and LSaO₂ (in group D vs 65.7 ± 0.21 65.8 ± 0.12 in group P).

Table 2 shows hemodynamic changes and SpO₂ of patients in the two groups at time points of predadministration of drugs (T0), immediately falling asleep patients (T1), during endoscopic operation (T2), and completion of the endoscopy (T3). Both groups were comparable in values of baseline MAP, HR, and SpO₂ at T0. Compared with group D, patients in group P displayed a significant decrease in MAP and SpO₂ at T1 (p < 0.05). HR of patients in group D at T1-T3 and in group P at T1 was obviously lower than that of patients at T0 (p < 0.05). However, none of the patients required any drug treatment for hypotension or bradycardia.

4. Discussion

SAHS refers to the repeated apnea and (or) lower ventilation throughout sleep caused by a variety of reasons, characterized by a series of clinical symptoms such as repeated hypoxemia and disorder sleep structure during sleep, sleepiness and fatigue in daytime, and memory deterioration, which has serious harm to patient's health as a result of systematic pathophysiological changes induced by long-lasting chronic hypoxemia, hypercapnia, and disorder sleep structure [10–14]. Upper airway reconstruction as for the classical surgical treatment is the important technique to treat SAHS in the present clinic; however, the efficacy of nonselective surgery is not often ideal because of the lack of preoperative assessment of airway [15–17]. The fiberoptic nasopharyngoscope is commonly used to observe the morphological structure of the upper airway under direct vision and more likely show the dynamic changes of the upper airway during sleep. In 1991, Croft and Pringle et al. [18] first developed the DISE, where the condition of patient's upper airway collapse is dynamically observed using the fiberoptic nasopharyngoscope, under the condition of “sleep” induced by sedative medication.

However, over the past two decades the major drugs in clinical use for DISE were mainly confined to intravenous anesthetics and sedative hypnotic drugs, such as propofol, etomidate, and benzodiazepines [2]. But the sleep induced by all of these drugs used in the clinic for DISE is not in accordance with the natural sleep under the condition of physiology, which interferes with the dynamic anatomical changes of airway causing apnea. Therefore, it is necessary to find a new drug that can induce sleep without interference with the dynamic changes of the upper airway.
Dexmedetomidine, selectively binding to postsynaptic α₂ adrenergic receptor located in the central nucleus of solitary tract, inhibits nervous impulse from sympathetic neurons in anterior horn of the spinal cord and reduces systemic sympathetic nervous tension and inhibits the release of norepinephrine from sympathetic nerve endings through activating presynaptic α₂ adrenergic receptor, which produces sedative, analgesic, anti-anxiety, obstructive sympathetic and opioids spare [19–22]. In recent years, accumulating evidences suggest that dexmedetomidine can prevent postoperative nausea and vomiting, and shivering, and has protective effects for nerves, heart, and kidney through multiple mechanisms. Characteristic sedative effect of dexmedetomidine is similar to physiological sleep with awareness, which puts patients in the condition of sleep, and they can easily be awakened to communicate with medical examiners [23]. These features of dexmedetomidine make it a very commonly used drug in the early tracheal extubation and fast channel cardiac anesthesia, and it is safely used for patients requiring mechanical ventilation or spontaneous breath due to its less respiratory depression.

In this study, in order to provide clinical evidence of dexmedetomidine as a sleep-induced drug for the fiberoptic nasopharyngoscope, the feasibility and safety of dexmedetomidine used for the fiberoptic nasopharyngoscope were explored. We found that patients in group P had significant hemodynamic changes manifesting a decrease in MAP and SpO₂ after infusion of propofol, which was associated with the side effects of propofol on different degrees of circular function inhibition and temporary respiratory depression. It increases potential risk of propofol as a sleep-induced drug for the endoscopy. However, although patients in group D had lower HR after administration, HR was still above 50 bpm, not requiring medication treatment, and there were no obvious hemodynamic change and respiratory inhibition. Further study showed that, compared with group D, although the time to fall asleep of patients in group P was significantly shorter, patients in group P displayed a significant prolongation in the duration of endoscopic examination and the wakeup time and an increase in the incidence of mask assisted ventilation for patients and false positive cases of SAHS, which decreased satisfaction of endoscopic performers.

Taken together, in the present study, we found that dexmedetomidine could satisfy the DISE requirement for patients undergoing SAHS and had no significant side effects on hemodynamic changes and less interference of breathing, which can be safely and effectively applied to DISE as the ideal induced sleep medication.

**Abbreviations**

- AHI: Apnea hypopnea index
- BMI: Body mass index
- DISE: Drug-induced sleep endoscopy
- HR: Heart rate
- LSaO₂: Lowest oxygen saturation
- MAP: Mean arterial pressure
- SAHS: Sleep apnea hypopnea syndrome

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.
Authors’ Contributions
L. L. Zhao and H. Liu contributed equally to this work.

References
[1] A. Vianello, V. Bisogni, C. Rinaldo et al., “Recent advances in the diagnosis and management of obstructive sleep apnea,” Minerva Medica, vol. 107, no. 6, pp. 437–451, 2016.
[2] J. W. Shteamer and R. C. Dedhia, “Sedative choice in drug-induced sleep endoscopy: A neuropharmacology-based review,” The Laryngoscope, vol. 127, no. 1, pp. 273–279, 2017.
[3] J. S. Cho, S. Soh, E. J. Kim et al., “Comparison of three sedation regimens for drug-induced sleep endoscopy,” Sleep and Breathing, vol. 19, no. 2, pp. 711–717, 2015.
[4] S. Anand, A. Bhatia, R. Kumar, H. Sapra, V. Gupta, and Y. Mehta, “Dexmedetomidine for monitored anesthesia care in patients undergoing liberation procedure for multiple sclerosis: An observational study,” Saudi Journal of Anaesthesia, vol. 6, no. 4, pp. 358–362, 2012.
[5] J.-L. Cao, Y.-P. Pei, J.-Q. Wei, and Y.-Y. Zhang, “Effects of intraoperative dexmedetomidine with intravenous anesthesia on postoperative emergence agitation/delirium in pediatric patients undergoing tonsillectomy without or with adenoidectomy: A CONSORT-prospective, randomized, controlled clinical trial,” Medicine (United States), vol. 95, no. 49, p. e5S66, 2016.
[6] H. W. Tuffaha, H. Reynolds, L. G. Gordon, C. M. Rickard, and P. A. S cuttham, “Value of information analysis optimizing future trial design from a pilot study on catheter securement devices,” Clinical Trials, vol. 11, no. 6, pp. 648–656, 2014.
[7] J. Charan and T. Biswas, “How to calculate sample size for different study designs in medical research?” Indian Journal of Psychological Medicine, vol. 35, no. 2, pp. 121–126, 2013.
[8] W. Hwang, J. Lee, J. Park, and J. Joo, “Dexmedetomidine versus remifentanil in postoperative pain control after spinal surgery: A randomized controlled study,” BMC Anesthesiology, vol. 15, no. 1, 2015.
[9] D.-J. Ge, B. Qi, G. Tang, and J.-Y. Li, “Intraoperative dexmedetomidine promotes postoperative analgesia and recovery in patients after abdominal colectomy: A CONSORT-prospective, randomized, controlled clinical trial,” Medicine (United States), vol. 94, no. 43, Article ID e1727, 2015.
[10] F. Gagnadoux, P. Priou, T. Urban, N. Meslier, and W. Trzepizur, “Sleep apneas, metabolic syndrome and cardiovascular risk: Data from the Pays de la Loire sleep cohort,” Revue de Pneumologie Clinique, vol. 73, no. 6, pp. 299–305, 2017.
[11] Y. Zhao, B. Y. Yu, Y. Liu, and Y. Liu, “Meta-Analysis of the Effect of Obstructive Sleep Apnea on Cardiovascular Events After Percutaneous Coronary Intervention,” American Journal of Cardiology, vol. 120, no. 6, pp. 1026–1030, 2017.
[12] U. Anttalainen, M. Tenhunen, V. Rimpilä et al., “Prolonged partial upper airway obstruction during sleep – an underdiagnosed phenotype of sleep-disordered breathing,” European Clinical Respiratory Journal, vol. 3, no. 1, p. 31806, 2016.
[13] M. Bosi, A. De Vito, R. Gobbi, V. Poletti, and C. Vicini, “The importance of obstructive sleep apnoea and hypopnea pathophysiology for customized therapy,” European Archives of Oto-Rhino-Laryngology, vol. 274, no. 3, pp. 1251–1261, 2017.
[14] F. Rezaetalab, F. Moharrari, S. Saberi, H. Asadpour, and F. Rezaetalab, “The correlation of anxiety and depression with obstructive sleep apnea syndrome,” Journal of Research in Medical Sciences, vol. 19, no. 3, pp. 205–210, 2014.
[15] H. Lin, E. M. Weaver, H. Lin, and M. Friedman, “Multilevel Obstructive Sleep Apnea Surgery,” in Sleep-Related Breathing Disorders, vol. 80 of Advances in Oto-Rhino-Laryngology, pp. 109–115, S. Karger AG, 2017.
[16] M. Camacho, V. Certal, and R. Capasso, “Comprehensive review of surgeries for obstructive sleep apnea syndrome,” Brazilian Journal of Otorhinolaryngology, vol. 79, no. 6, pp. 780–788, 2013.
[17] S. M. Caples, J. A. Rowley, J. R. Prinsell et al., “Surgical modifications of the upper airway for obstructive sleep apnea in adults: a systematic review and meta-analysis,” SLEEP, vol. 33, no. 10, pp. 1396–1407, 2010.
[18] C. B. Croft and M. Pringle, “Sleep nasendoscopy: a technique of assessment in snoring and obstructive sleep apnoea,” Clinical Otolaryngology & Allied Sciences, vol. 16, no. 5, pp. 504–509, 1991.
[19] J. Attiri, R. Sharan, V. Makkar, K. Gupta, R. Khetarpal, and A. Kataria, “Conscious sedation: Emerging trends in pediatric dentistry,” Anesthesia: Essays and Researches, vol. II, no. 2, p. 277, 2017.
[20] N. Khurmi, P. Patel, M. Kraus, and T. Trentman, “Pharmacologic Considerations for Pediatric Sedation and Anesthesia Outside the Operating Room: A Review for Anesthesia and Non-Anesthesia Providers,” Pediatric Drugs, vol. 19, no. 5, pp. 435–446, 2017.
[21] C. H. King, S. S. Beutler, A. D. Kaye, and R. D. Urman, “Pharmacologic Properties of Novel Local Anesthetic Agents in Anesthesia Practice,” Anesthesiology Clinics, vol. 35, no. 2, pp. 315–325, 2017.
[22] V. Nguyen, D. Tiemann, E. Park, and A. Salehi, “Alpha-2 Agonists,” Anesthesiology Clinics, vol. 35, no. 2, pp. 233–245, 2017.
[23] R. D. Sanders and M. Maze, “Alpha2-adrenoceptor agonists,” Current Opinion in Investigational Drugs, vol. 8, pp. 25–33, 2007.